BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16235577)

  • 1. Reader comments on complementary and alternative medicine programs.
    Lee CO
    Clin J Oncol Nurs; 2005 Oct; 9(5):510; author reply 510-1. PubMed ID: 16235577
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 3. [Soviet-American cooperation in experimental and clinical chemotherapy from 1972 to 1979].
    Peredovchikova NI; Kiselev AV; Puchkov IuI; Komarova LE; Gorbunova VA
    Vopr Onkol; 1980; 26(12):3-6. PubMed ID: 7008350
    [No Abstract]   [Full Text] [Related]  

  • 4. The linear array.
    Zubrod CG; Schepartz SA; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):13-4. PubMed ID: 927488
    [No Abstract]   [Full Text] [Related]  

  • 5. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations.
    Natl Cancer Inst Monogr; 1980 Dec; (55):1-179. PubMed ID: 7010179
    [No Abstract]   [Full Text] [Related]  

  • 6. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
    Buchanan DR; White JD; O'Mara AM; Kelaghan JW; Smith WB; Minasian LM
    J Clin Oncol; 2005 Sep; 23(27):6682-9. PubMed ID: 16170176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening at the National Cancer Institute.
    Goldin A; Venditti JM; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):37-48. PubMed ID: 337155
    [No Abstract]   [Full Text] [Related]  

  • 8. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM
    Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
    [No Abstract]   [Full Text] [Related]  

  • 9. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
    Anderson SJ
    J Clin Oncol; 2006 Aug; 24(24):3821-2. PubMed ID: 16921032
    [No Abstract]   [Full Text] [Related]  

  • 10. History of the National Cancer Institute and the plant screening program.
    Schepartz SA
    Cancer Treat Rep; 1976 Aug; 60(8):975-7. PubMed ID: 791487
    [No Abstract]   [Full Text] [Related]  

  • 11. Lost in translation.
    Hays JC
    Public Health Nurs; 2007; 24(6):489-90. PubMed ID: 17973725
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotechnology transfer at the National Institutes of Health.
    Chen PS
    Qual Assur; 1993 Dec; 2(4):345-52. PubMed ID: 7952969
    [No Abstract]   [Full Text] [Related]  

  • 13. Proceedings: Anticancer drug development programs: a comparison of approaches in the United States, the Soviet Union, Japan, and Western Europe.
    Carter SK
    Natl Cancer Inst Monogr; 1974 Feb; 40():31-45. PubMed ID: 4819407
    [No Abstract]   [Full Text] [Related]  

  • 14. Complementary and alternative medicine patients are talking about: black cohosh.
    Lee CO
    Clin J Oncol Nurs; 2005 Oct; 9(5):628-9. PubMed ID: 16235591
    [No Abstract]   [Full Text] [Related]  

  • 15. Macro trends in pharmaceutical innovation.
    Cohen FJ
    Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flasks, fibres and flanks--pre-clinical tumour models for predicting clinical antitumour activity.
    Newell DR
    Br J Cancer; 2001 May; 84(10):1289-90. PubMed ID: 11355935
    [No Abstract]   [Full Text] [Related]  

  • 17. National Center for Complementary and Alternative Medicine perspectives for complementary and alternative medicine research in cardiovascular diseases.
    Wong SS; Nahin RL
    Cardiol Rev; 2003; 11(2):94-8. PubMed ID: 12620133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harvard turns to matchmaking to speed translational research.
    Wadman M
    Nat Med; 2008 Jul; 14(7):697. PubMed ID: 18607352
    [No Abstract]   [Full Text] [Related]  

  • 19. Complementary and alternative medicine research: a National Cancer Institute perspective.
    White JD
    Semin Oncol; 2002 Dec; 29(6):546-51. PubMed ID: 12516037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCI launches an innovative design for a breast cancer clinical trial.
    Whitworth A
    J Natl Cancer Inst; 2006 Sep; 98(17):1178-9. PubMed ID: 16954467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.